What is HC Wainwright’s Forecast for Myomo FY2030 Earnings?

Myomo, Inc. (NYSEAMERICAN:MYO) – HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of Myomo in a research note issued on Tuesday, March 10th. HC Wainwright analyst S. Lee anticipates that the company will earn $0.35 per share for the year. The consensus estimate for Myomo’s current full-year earnings is ($0.18) per share.

A number of other equities research analysts also recently issued reports on MYO. Craig Hallum reaffirmed a “buy” rating on shares of Myomo in a research report on Tuesday. Ascendiant Capital Markets dropped their target price on shares of Myomo from $10.50 to $10.00 and set a “buy” rating on the stock in a research report on Friday, November 21st. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $7.67.

Myomo Stock Down 16.8%

MYO opened at $0.68 on Wednesday. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.49 and a quick ratio of 2.10. The company’s 50-day moving average is $0.86 and its 200 day moving average is $0.92. Myomo has a fifty-two week low of $0.64 and a fifty-two week high of $6.30. The firm has a market capitalization of $25.95 million, a P/E ratio of -1.82 and a beta of 1.17.

Hedge Funds Weigh In On Myomo

Institutional investors have recently added to or reduced their stakes in the stock. Rosalind Advisors Inc. grew its position in shares of Myomo by 33.0% during the 2nd quarter. Rosalind Advisors Inc. now owns 3,595,788 shares of the company’s stock valued at $7,767,000 after acquiring an additional 892,127 shares during the period. Jefferies Financial Group Inc. bought a new stake in shares of Myomo in the 4th quarter worth approximately $641,000. Geode Capital Management LLC raised its holdings in shares of Myomo by 160.8% in the 2nd quarter. Geode Capital Management LLC now owns 669,281 shares of the company’s stock worth $1,446,000 after purchasing an additional 412,631 shares during the period. Centiva Capital LP purchased a new position in Myomo in the third quarter valued at approximately $190,000. Finally, Prescott Group Capital Management L.L.C. purchased a new position in Myomo in the fourth quarter valued at approximately $169,000. Institutional investors own 44.99% of the company’s stock.

About Myomo

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.